scholarly journals Molecular epidemiology of rotavirus in the era of vaccination

2012 ◽  
Vol 33 (2) ◽  
pp. 64 ◽  
Author(s):  
Celeste Donato

Rotavirus is the principal aetiological agent of severe acute gastroenteritis in young children worldwide. Two vaccines, Rotarix [GlaxoSmithKline] and RotaTeq [Merck], have been developed to address the large burden of disease experienced worldwide. Both vaccines have been successful in decreasing morbidity and mortality associated with rotavirus gastroenteritis. Minor fluctuations in rotavirus epidemiology have been observed since vaccine introduction. However, it is unclear whether these observations are due to selection pressures specific to vaccine introduction or due to natural genotype fluctuations.

2018 ◽  
Vol 90 (6) ◽  
pp. 1040-1046 ◽  
Author(s):  
Nusrat Khandoker ◽  
Aksara Thongprachum ◽  
Sayaka Takanashi ◽  
Shoko Okitsu ◽  
Shuichi Nishimura ◽  
...  

2016 ◽  
Vol 89 (5) ◽  
pp. 809-817 ◽  
Author(s):  
Ernest A. Wandera ◽  
Shah Mohammad ◽  
Satoshi Komoto ◽  
Yoshimasa Maeno ◽  
James Nyangao ◽  
...  

Author(s):  
Shuvra Kanti Dey ◽  
Nadim Sharif ◽  
Baki Billah ◽  
Tanjir Tarek Ibn Siddique ◽  
Tarequl Islam ◽  
...  

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S700-S701
Author(s):  
Cristina Carias ◽  
Susanne Hartwig ◽  
M Nabi Kanibir ◽  
Ya-Ting Chen

Abstract Background While the burden of Rotavirus Gastroenteritis (RGE) is well recognized in young children, it is less so in older adults. However, older adults are also at high-risk of Acute Gastroenteritis (AGE) severe outcomes. In this review, we thus aimed to comprehensively assess RGE burden and vaccination impact in older individuals. Methods We performed a systematic literature review with PubMed and Scopus, from 2000 to 2019, using MESH and free-range terms. We included only studies that reported the incidence, and/or RV vaccination impact, in adults aged 60 and above and using regional specific data-sources. Results We analyzed 11 manuscripts for individuals aged 60 and above (Figure 1). Studies spanned Australia, Sweden, Netherlands, Canada (2), Germany (2), UK (2), and the US (2). Yearly inpatient RV incidence varied between 1.6 per 100,000 in Australia for those 65+ (retrospective database analyses, pre-vaccine); and 26 per 100,000 for those 85+ in Canada (modeling estimates for 2006-10, pre-vaccine). The incidence rate ratio for inpatient RGE between the post and pre-vaccine periods for those 65+ was 0.57 [95% CI: 0.10 – 3.15] in Canada, but 2.24 [95%CI: 1.78-2.83] in Australia, which may be due to increased testing for RV in the elderly post-vaccine. Reductions in the post-vaccination burden of RV and AGE among 60+ were reported in the UK (2 studies), and the US (2 studies) via retrospective database analyses In the UK, post-vaccine reductions in AGE health care-utilization were reported in the Emergency Department (21%), and outpatient centers (walk-in centers: 47%; general practice consultations: 36%). Retrospective database analyses documenting the incident rate ratio (IRR) of Rotavirus Gastroenteritis (RGE) and Acute Gastroenteritis (AGE) in older adults between the pre and post-vaccine period. Retrospective database analyses documenting the incident rate ratio (IRR) of Rotavirus Gastroenteritis (RGE) and Acute Gastroenteritis (AGE) in older adults between the pre and post-vaccine period. Conclusion While the burden of RGE mainly falls on young children, it also affects older adults. Retrospective database analyses reveal that, likely due to indirect vaccination benefits, increases in RV vaccination coverage have had an impact on lowering RGE, and AGE cases and healthcare utilization in older adults, a group at high-risk of severe outcomes for AGE. Disclosures Cristina Carias, PhD, Merck (Employee, Shareholder) Susanne Hartwig, n/a, MSD Vaccins (Employee) M.Nabi Kanibir, MD, Merck/MSD (Employee, Shareholder) Ya-Ting Chen, PhD, Merck & Co., Inc. (Employee, Shareholder)


Author(s):  
Kiyoshi Kyo ◽  
Chika Takano ◽  
Yuki Kasuga ◽  
Erika Ogawa ◽  
Mika Ishige ◽  
...  

1998 ◽  
Vol 169 (5) ◽  
pp. 252-256 ◽  
Author(s):  
John B Carlin ◽  
Patty Chondros ◽  
Paul Masendycz ◽  
Helen Bugg ◽  
Ruth F Bishop ◽  
...  

2014 ◽  
Vol 143 (2) ◽  
pp. 316-324 ◽  
Author(s):  
C. F. MANSO ◽  
J. L. ROMALDE

SUMMARYThe high incidence of norovirus (NoV) infections seems to be related to the emergence of new variants that evolved by genetic drift of the capsid gene. In this work, that represents a first effort to describe the molecular epidemiology of NoV in the northwest of Spain, a total of eight different NoV genotypes (GII.1, GII.3, GII.4, GII.6, GII.7, GII.12, GII.13, GII.14) were detected. The major genotypes observed were GII.4 (45·42%) and GII.14 (34·9%), being detected in all age groups. In addition, and although most of GII.4 sequences belonged to 2006b (7·2%) and 2010 (50·35%) variants, the presence of new NoV variants was observed. Phylogenetic analysis revealed that a high number of GII.4 sequences (35·24%) could be assigned to the newly emerging Sydney 2012 variant, even during late 2010. The high prevalence of NoV GII.14 observed in this study may indicate the emergence of this genotype in Spain.


2019 ◽  
Vol 91 (5) ◽  
pp. 738-743 ◽  
Author(s):  
Akongnwi E. Mugyia ◽  
Valentine N. Ndze ◽  
Jane-Francis T. K. Akoachere ◽  
Hannah Browne ◽  
Angeline Boula ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document